Figure 4 | Scientific Reports

Figure 4

From: Treatment with fibroblast growth factor 19 increases skeletal muscle fiber size, ameliorates metabolic perturbations and hepatic inflammation in 5/6 nephrectomized mice

Figure 4

FGF19 corrects uremia-mediated insulin resistance in association with suppressed hepatic gluconeogenesis genes expression. (A) Fasted blood glucose. (B) Glucose levels during an i.p. GTT (2 g/kg) and (C) AUC (0–60 min) in control and CKD mice after FGF19 or vehicle treatment. Relative mRNA expression of (D) Pi3K p85a (E) Gys2 and (F) G6pc1 in Sham and CKD mice after FGF19 or vehicle treatment. (G) Percentage of Oil Red O staining of soleus muscle in Sham and CKD mice after FGF19 or vehicle treatment. Relationship between Oil Red O staining of soleus muscle and (H) fasted glycemia or (I) AUC glucose during ip-GTT. (J) Representative images of muscle sections stained with Oil Red O. Tbp (TATA-Box Binding Protein) was used as reference gene to normalize the results. Results are expressed as the ratio of target mRNA levels to housekeeping gene mRNA levels and normalized to the levels in Sham mice. Data are expressed as mean ± SEM for n = 9–15 animals in each group. Statistical analysis was done using a one-way ANOVA test *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: AUC: area under curve, CKD: chronic kidney disease, G6pc1: glucose-6-phosphatase, Gys2: glycogen synthase, Pi3k: phosphoinositide 3-kinase, n.s., not significant.

Back to article page